Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension

INTRODUCTION: High efficacy and safety of 8-week glecaprevir/pibrentasvir (G/P) therapy was seen in hepatitis C (HCV)-infected, treatment-naïve (TN), compensated cirrhosis (CC) patients in EXPEDITION-8. To provide further understanding of the efficacy of G/P treatment in HCV-infected TN patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Robert S., Collins, Michelle A., Strasser, Simone I., Emmett, Amanda, Topp, Andrew S., Burroughs, Margaret, Ferreira, Rosa, Feld, Jordan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960502/
https://www.ncbi.nlm.nih.gov/pubmed/35174470
http://dx.doi.org/10.1007/s40121-022-00599-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8960502/
https://www.ncbi.nlm.nih.gov/pubmed/35174470
http://dx.doi.org/10.1007/s40121-022-00599-8

Ejemplares similares